Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
08:05am, Tuesday, 27'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
Denali Therapeutics Announces $500 million Private Placement Equity Financing
08:00am, Tuesday, 27'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
09:10am, Thursday, 08'th Feb 2024
The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to improve
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
Denali's (DNLI) Pipeline Progresses Despite Stiff Competition
11:01am, Friday, 26'th Jan 2024
Denali (DNLI) forms strategic collaborations with bigwigs like Sanofi and Biogen to advance its pipeline. However, high dependence on partners for revenues remains a concern.
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
01:57pm, Tuesday, 02'nd Jan 2024
Americans live longer than ever, and a handful of biotech stocks stand at the forefront of longevity's future. Many misconceive anti-aging stocks as peddling some magic pill that inexplicably makes yo
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
11:17am, Friday, 22'nd Dec 2023
Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.
Does Denali Therapeutics Inc. (DNLI) Have the Potential to Rally 123.38% as Wall Street Analysts Expect?
11:17am, Thursday, 21'st Dec 2023
The consensus price target hints at a 123.4% upside potential for Denali Therapeutics Inc. (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
Wall Street Analysts See a 163.82% Upside in Denali Therapeutics Inc. (DNLI): Can the Stock Really Move This High?
11:17am, Monday, 27'th Nov 2023
The consensus price target hints at a 163.8% upside potential for Denali Therapeutics Inc. (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates
07:33pm, Tuesday, 07'th Nov 2023
Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.84 per share a year ago.
Wall Street Analysts Think Denali Therapeutics Inc. (DNLI) Could Surge 121.53%: Read This Before Placing a Bet
11:17am, Monday, 06'th Nov 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in Denali Therapeutics Inc. (DNLI). While the effectiveness of this highly sought-after metric is questi
Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report?
12:47pm, Thursday, 07'th Sep 2023
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?
Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues
01:45pm, Thursday, 10'th Aug 2023
Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.
